reports
Moody's: Takeda's latest offer to acquire Shire would further increase...
Moody's Japan K.K. says that Takeda Pharmaceutical Company Limited's (A1 negative) latest proposal to acquire a global biopharmaceutical company, Shire plc (Baa3 positive), if it goes ahead, will place even greater downward pressure on Takeda's A1 ratings. "This huge acquisition bod...
- Please Change Name John C Forrey
- Please Change Name Kailash Chhaya
Takeda Pharmaceutical Company Limited: Update to credit analysis
CORPORATES CREDIT OPINION 6 September 2017 Update RATINGS Takeda Pharmaceutical Company Limited Domicile Japan Long Term Rating A1 Type LT Issuer Rating - Fgn Curr Outlook Negative Please see the ratings section  at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Kailash Chhaya 81-3-5408-4201
- Please Change Name John C Forrey
- Please Change Name Kailash Chhaya
- Please Change Name Kailash Chhaya
Moody's assigns A1 rating to Takeda Pharmaceutical's USD notes (Japane...
Contact: æ±äº¬ æ±äº¬ カイラシュ・ ãƒãƒ£ãƒ¤ çœŸé‹ ç¾Žç©‚å ä¸»ä»»æ ¼ä»˜ã‚¢ãƒŠãƒªã‚¹ãƒˆï¼VP シニア・アナリスト æ ¼ä»˜è²¬ä»»è€…ï¼ï½±ï½¿ï½¼ï½´ï½²ï¾„ï½¥ï¾ï¾ˆï½°ï½¼ï¾žï¾ï½¸ï¾žï½¥ï¾ƒï¾žï½¨ï¾šï½¸ï¾€ï½° コーãƒãƒ¬ãƒ¼ãƒˆãƒ»ãƒ•ã‚¡ã‚¤ãƒŠãƒ³ã‚¹ãƒ»ã‚°ãƒ«ãƒ¼ãƒ— コーãƒãƒ¬ãƒ¼ãƒˆãƒ»ãƒ•ã‚¡ã‚¤ãƒŠãƒ³ã‚¹ãƒ»ã‚°ãƒ«ãƒ¼ãƒ— ãƒ ãƒ¼ãƒ‡ã‚£ãƒ¼ã‚ºãƒ»ã‚¸ãƒ£ãƒ‘ãƒ³æ ªå¼ä¼šç¤¾ ãƒ ãƒ¼ãƒ‡ã‚£ãƒ¼ã‚ºãƒ»ã‚¸ãƒ£ãƒ‘ãƒ³æ ªå¼ä¼šç¤¾ ãŠå®¢æ§˜å°‚用電話番å·ï¼š03-5408-4100 å ±é“関係者電話番å·ï¼š03-540...
- Please Change Name Chhaya
- Kailash
Takeda Pharmaceutical Company Limited (Japanese translation)
CORPORATES JANUARY 11, 2017 ãƒ ãƒ¼ãƒ‡ã‚£ãƒ¼ã‚ºãƒ»ã‚¸ãƒ£ãƒ‘ãƒ³æ ªå¼ä¼šç¤¾ CREDIT OPINION 目次 : æ ¼ä»˜ã®æ ¹æ‹ 1 æ ¼ä»˜ã‚’æ”¯ãˆã‚‹è¦å› 2 æ ¼ä»˜ã‚’åœ§è¿«ã™ã‚‹è¦å› 2 æ ¼ä»˜ã®è¦‹é€šã— 2 å°†æ¥ã®æ ¼ä¸Šã’ã«ã¤ãªãŒã‚‹è¦å› 2 å°†æ¥ã®æ ¼ä¸‹ã’ã«ã¤ãªãŒã‚‹è¦å› 2 主è¦è²¡å‹™æŒ‡æ¨™ 3 æ ¼ä»˜ã«é–¢ã™ã‚‹è©³ç´°ãªæ¤œè¨Ž
- Please Change Name Chhaya
- Kailash
Takeda's $5.4 Billion Acquisition of ARIAD Will Increase Leverage
ISSUER COMMENT CORPORATES JANUARY 12, 2017 What is Moody’s Credit Outlook? Published every Monday and Thursday morning, Moody's Credit Outlook informs our research clients of the credit implications of current events. Takeda’s $5.4 Billion Acquisition of ARIAD Will Increase Leverage From Credit Outlook On Monday, Takeda Pharmaceutical Company Limited (A1 review for downgrade) announced that i
- Please Change Name Chhaya
Takeda Pharmaceutical Company Limited: Update after placing the rating...
CORPORATES CREDIT OPINION 11 January 2017 Update RATINGS Takeda Pharmaceutical Company Limited Domicile Japan Long Term Rating A1 , Possible Downgrade Type LT Issuer Rating - Fgn Curr Outlook Rating(s) Under Review Please see the ratings section at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Kailash Chhaya
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.